Fig. 6

CircMET allows non-invasive tracking of MET-driven acquired resistance and therapy response in cancer patients. a Upper panel: clinical history of lung adenocarcinoma case #5. Black and yellow arrows on CT scans indicate primary and secondary lung lesions, respectively, while green arrows indicate liver lesions. FISH for MET in the post-therapy biopsy (case #5R) is shown on the right. MET is labeled in green and centromeres in red. Lower panel: dPCR on circMET along with real-time PCR on EGFR T790M and EGFR Ex19del upon cell-free DNA (cfDNA) extraction from liquid biopsies longitudinally obtained at the indicated time points (N/A = not available). b Immunohistochemical and real-time PCR analyses on FFPE biopsies collected before and after therapy (case #5 and case #5R) (scale bar = 100 μm). c dPCR analysis of circMET upon cfRNA extraction along with ddPCR-based Copy Number Variation (CNV) assessment on cfDNA from liquid biopsies obtained at the indicated time points of a previously described colorectal cancer case [44, 47]. Data are expressed as mean ± SEM